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J. M. Guti6rrez and B. Lomonte. Phospholipase A2 myotoxins from Bothrops 
snake venoms. Toxicon 33, 1405-1424.--Several myotoxins have been isolated 
from Bothrops nake venoms during the last 10 years. All of them are group 
II basic phospholipases A2, although some lack enzymatic activity (i.e. Lys-49 
variants). These myotoxins appear as an antigenically related family of proteins 
occurring in many, but not all, Bothrops venoms, bearing a close structural and 
antigenic relationship to toxins found in other crotalid venoms of the genera 
Agkistrodon and Trimeresurus. Myotoxins are quantitatively important venom 
components in some Bothrops pecies. Intramuscular injection of Bothrops 
myotoxins leads to a rapid series of drastic degenerative events, probably 
initiated at the plasma membrane l vel, which culminate in a selective skeletal 
muscle necrosis. This in vivo specificity contrasts with the ability of myotoxins 
to lyse many types of cells in culture. Muscle damage, as well as cytolysis and 
liposome disruption, occur in conditions where phospholipase A2 activity 
is inhibited, although enzymatic activity might enhance myotoxin actions. 
A membrane receptor for Bothrops myotoxins has not been identified 
yet. A working hypothesis on the mechanism of action is proposed. Current 
evidence suggests that these toxins interact with biological membranes via a 
molecular egion distinct from their known catalytic site. The active region is 
likely to be formed by a combination of basic and hydrophobic amino acid 
residues near the C-terminus of the protein, which allow electrostatic nter- 
action and bilayer penetration. These events may lead to membrane destabiliza- 
tion and loss of selective permeability to ions such as calcium, both of which 
appear to be important mediators in the process of muscle necrosis. 
INTRODUCTION 
Muscle necrosis is a relevant local effect induced by many snake venoms, as it may lead 
to permanent tissue loss, disability, and amputation (Rosenfeld, 1971; Kerrigan, 1991; 
Nishioka and Silveira, 1992). In Latin America, most snakebite nvenomations are caused 
by Bothrops pp. and often course with local myonecrosis (Rosenfeld, 1971; Bolafios, 1982; 
Otero et al., 1992). During the last few years, there has been a growing interest in the study 
of venom components responsible for myonecrosis and their mode of action. As a result, 
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several myotoxins from Bothrops venoms have been isolated and characterized, and some 
progress has been made towards understanding their mechanism of action and the 
pathogenesis of myonecrosis. All of them have phospholipase A 2 (PLA2) structure, 
although some lack enzymatic activity. This article summarizes the current knowledge on 
Bothrops myotoxins, 10 years after the first toxin of this group was isolated from the venom 
of B. asper (Guti~rrez et aL, 1984a). 
BOTHROPS MYOTOXINS: ISOLATION AND BIOCHEMICAL CHARACTERIZATION 
Isolation strategies 
Almost all snake toxins with a direct muscle damaging activity isolated to date are basic 
proteins (Mebs and Ownby, 1990; Harris, 1991). Therefore, procedures for their isolation 
usually include a cation-exchange chromatographic step, to separate them from the bulk 
of acidic venom components. A list of myotoxins isolated from Bothrops venoms is 
presented in Table 1. In many cases, myotoxins are the last components eluting from 
cation-exchange columns using salt gradients at neutral pH. During purification, fractions 
may be screened for myotoxicity in mice, by intramuscular injections in the range of 
10-100/~g protein. It should be noted that Bothrops myotoxins may not be as potent as 
some elapid counterparts, for which a dose of ~, 1 mg/kg body weight has been suggested 
as a guideline (Harris, 1991, 1992). However, the lower potency is compensated bythe high 
amount of venom injected by many Bothrops nakes and the relatively high concentration 
of myotoxins (as much as 25% in the venom of B. jararacussu, Moura et al., 1991a; 
15-25% in B. asper venom, unpublished results), suggesting that their activity can be 
clinically relevant. 
Myotoxicity can be assessed by histological evaluation or, more conveniently, by 
measurement of plasma (or serum) creatine kinase (EC 2.7.3.2) levels 1-3 hr after injection 
(Gutirrrez et al., 1984a, 1991; Moura et al., 1990, 1991a; Diaz et al., 1992). Screening for 
PLA2 activity is another convenient way to follow the purification of myotoxins, although 
PLA2 isoforms devoid of enzymatic activity (i.e. Lys-49 variants) would be missed by this 
approach, and many PLA2s lack myotoxic effect. Owing to their high number of intrachain 
disulfide bridges, PLA2 myotoxins are generally rigid and stable proteins (Scott et al., 
1990), which do not denature under usual handling conditions during purification and 
assay. 
Isoforms 
It is common to find isoforms of PLA2 in snake venoms of a single species or even a 
single individual (Faure and Bon, 1987; Takasaki et al., 1990; Valiente et al., 1992, 
Fukagawa et al., 1993). Bothrops venoms also present a diversity of myotoxic PLA2 
isoforms. Differences in the expression of myotoxin isoforms at the individual evel have 
been shown in B. asper, where at least five variants can be distinguished electrophoretically 
(Lomonte and Carmona, 1992). Recent cloning studies on Trimeresurus flavoviridis 
myotoxic PLA2s have shown the existence of six different isozyme genes (Nakashima et al., 
1993). There is an interesting ontogenetic regulation of myotoxin expression in B. asper, 
since newborn snakes appear not to express any isoform before 1 month of age (Lomonte 
et al., 1987b; Lomonte and Carmona, 1992). 
Bothrops myotoxin isoforms described to date cannot be resolved by separation 
techniques based on molecular size, such as gel filtration or SDS-PAGE. Thus, the use 
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of SDS-PAGE as the only criterion for myotoxin homogeneity can be misleading. 
Ion-exchange columns or charge-based electrophoretic techniques can usually resolve 
myotoxin isoforms differing in their net charge. An exception may be isoelectric focusing 
using broad pH gradients (i.e. range 3-9), which fail to resolve the highly basic myotoxins. 
Reverse-phase HPLC has also been useful in the separation of isoforms (Bruses et al., 
1993). 
In B. asper venom, two sequenced myotoxin isoforms (II and III) differ in primary 
structure (Kaiser et al., 1990; Francis et al., 1991), therefore being products of related, but 
distinct genes, probably arising by duplication and divergence (Davidson and Dennis, 
1990; Nakashima et al., 1993). Sequence microheterogeneity hasbeen observed in both 
myotoxins, as well as in bothropstoxin I from B. jararacussu (Cintra et al., 1993). Since 
snake venom PLA2s described so far are not glycosylated, additional isoform diversity 
cannot result from glycosylation microheterogeneity. It is possible that other post-trans- 
lational modifications such as acylation, described for several PLA2s (Cho et al., 1988; 
Tomasselli et al., 1989), might add to the molecular diversity of Bothrops myotoxins. 
Recent data demonstrate hat B. asper myotoxin II can undergo autocatalytic acylation 
(Pedersen et aL, 1995), as discussed in Structure-function relationships (pp. 1417-1418). 
While all myotoxins in Bothrops venoms have PLA 2 structure, some of them lack 
catalytic activity owing to critical amino acid substitutions in the calcium-binding loop, 
especially Lys for Asp-49. The discovery of a Ser-49 myotoxic PLA2, ammodytin L, in the 
venom of Vipera ammodytes (Krizaj et al., 1991) prompts for the possible presence of 
variants other than Lys-49 replacing Asp-49 in Bothrops venoms. Protein engineering 
studies (Van den Bergh et al., 1989) demonstrated that the low enzymatic activities 
originally reported for some Lys-49 PLA2s (Maraganore et al., 1984) are most probably 
due to contaminant traces of Asp-49 enzymes (Van den Bergh et al., 1989; Scott et al., 
1992). The existence and wide distribution of enzymatically inactive Lys-49 myotoxins in 
Table 1. Bothrops myotoxins 
PLA 2 
Species Toxin name Mol. wt pl activity* Reference 
B. asper myotoxin I 10,700t n.d. (+) Guti~rrez et al. (1984a) 
B. asper myotoxin II 13,300~ n.d. ( - )  Lomonte and Guti~rrez (1989) 
B. asper myotoxin III 13,900~ >9.5 (+) Kaiser et al. (1990) 
B. asper myotoxin IV 15,500:~ n.d. ( - )  Diaz et aL (1995) 
B. asper myotoxic PLA 2 14,100 n.d. (+) Mebs and Samejima (1986) 
B. nurnmifer myotoxin 16,000J/ n.d ( - )  Guti~rrez et al. (1986b) 
B. nummifer myotoxin peak IV 15,000:~ ~ 10.6 n.d. Brusrs et aL (1993) 
B. jararacussu Sm-SPIv 13,869§ ~8.2 ( - )  Homsi-Brandeburgo et aL (1988) 
(bothropstoxin I) Cintra et aL (1993) 
B. jararacussu bothropstoxin II 15,78~ ~7.7 (+) Homsi-Brandeburgo et aL (1988) 
B. insularis myotoxin 15,000~/ n.d. (+) Selistre et aL (1990) 
B. atrox myotoxin 13,400~ n.d. (+) Lomonte et al, (1990b) 
B. moojeni myotoxin I 13,400~ n.d. ( - )  Lomonte et aL (1990b) 
B. moojeni myotoxin II 13,400~ n.d. ( - )  Lomonte et al. (1990b) 
B. moojeni MOO-1 15,000:~ n,d. (+) Moura et aL (1991a) 
B. pradoi PRA-1 15,000 n.d. (+) Moura et al. (1991a) 
B. godmani myotoxin I 14,300~ ~8.2 (+) Diaz et al. (1992) 
B. godrnani myotoxin II 13,400~ ~8.9 ( - )  Diaz et al. (1992) 
Monomeric mol. wts estimated by t gel filtration; J/ SDS-PAGE; § amino acid composition, .d., Not 
determined. 
*( - )  refers to lack of activity or extremely low activity (lower than 2 #Eq fatty acid mg -t min-l). Some 
of these myotoxins have been shown to be Lys-49 variants. 
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Table2.~uen~sofmyotoxicphospholipasesA2~omBo~ropsvenoms 
I 5 10 15 20 25 
(a) S L I E F A K M I L E E T K R L P F P Y - -  Y T T Y G C 
(~ S L F E LGKM I LQ E TG K N PAK S - -YGAYG C 
S L F E LGKM I LQ E TG K N PAK S - -YGAYG C 
~) S LV  E LGKM I LQE TG K N P L T S - -YGVYG C 
~) S L V E LGKM I LQ E TG K N PV  T - - - -YGA Y 
30 35 40 45 50 
~) YCGWGGQGQ PKDAT D R C C F VHDC C YG - -  
(b) N C G V L G R G K P K D A T D R C C Y V H K C C Y K - -  
(c) N C G V L G R G K P K D A T D R C C Y V H K C C Y K - -  
(d) N C G V G S R H K P K D D T D R C C Y V H K C C Y 
55 60 65 70 75 80 
(a) - - - -  K L S N C K P K T D R Y S Y S R K S G V 
- - - -K  L TGC NP  K K DR Y S Y SWKDK T 
~) - - - -K  L TGC NP  K K DRY S Y SWKDK T 
85 90 95 1~ 105 
(a) 11  C - -  G E G T P C E K Q I C E C D K A A A V C F R E 
(b) I V C -  G E N N S C L K E L C E C D K A V A I C L R E 
~) I V C - -G  ENN P C LKE  L C E CDK AVA I C L R E 
i10 115 120 125 130 
(a) N L R T Y K K R Y M A Y P D L/F L C -  K K P A E/D K/P C 
(b) N L N T Y N K K Y R Y Y L K P L/F C - - - -  K K A D A C 
(c) N L G T Y N K K Y R Y H L K P F C - - - -  K K A D P C 
(a) B. ~r  myoto~n III ~a i~r  et aL, 1990); ~ B. asper myotoxin II (Francis et aL, 1991); ~) B.~rara~ssu 
bothropstoxin I ~intra et aL, 1993); ~) B. atrox PLA 2 ~-te~inal  51 residues), (Mara~nore et al., 1984); 
~) B. ~per myotoxin IV (N-te~inal 24 ~sidues) (Di~ et al., 1995). 
Bothrops spp., as well as in other crotalids such as Agkistrodon spp. (Maraganore t al., 
1984) and Trimeresurus pp. (Yoshizumi et al., 1990; Liu et al., 1990, 1991), is intriguing 
from an evolutionary point of view. One may wonder why the PLA2-inactive variants, 
probably originating from active counterparts, have been maintained uring evolution, 
and appear to be quantitatively important  components of some venoms. To date, no 
striking qualitative differences in the in vivo pharmacological properties between Lys-49 
and Asp-49 isozymes have been reported. In B. asper venom it was surprising to detect 
a Lys-49 isoform (myotoxin II) in every individual, in contrast o enzymatically active 
isoforms (myotoxins I and III) which varied in their expression among different individuals 
(Lomonte and Carmona,  1992). 
Structural analysis 
Bothrops myotoxins are classified as group II PLA2s, together with all crotalid/viperid 
venom enzymes and the secreted non-pancreatic mammal ian PLA2 (Davidson and Dennis, 
1990). Some Bothrops myotoxins have been shown to occur as dimers: B. asper myotoxins 
II and I I I  (Lomonte and Guti~rrez, 1989; Francis et al., 1991), B. nummifer myotoxin 
(Gutirrrez et al., 1986b; Bruses et aL, 1993) and B. insularis myotoxin (Selistre t al., 1990). 
Amino acid composit ion analysis indicates that these toxins are rich in basic and 
hydrophobic amino acids (Gutirrrez et aL, 1984a, 1989; Homsi-Brandeburgo et al., 1988; 
Selistre t al., 1990; Lomonte and Gutirrrez, 1989; Lomonte et al., 1990b; Diaz et aL, 1992, 
1995b). Complete sequences of three toxins are available (Table 2). B. asper myotoxin II 
and Bothrops jararacussu bothropstoxin I are highly homologous Lys-49 PLA#,  differing 
by only 4 or 5 out of 121 residues (Francis et al., 1991; Cintra et aL, 1993). Bothrops asper 
myotoxin II I  is an Asp-49 PLA~ of 122 residues (Kaiser et al., 1990). There is higher 
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homology between Lys-49 myotoxins of different genera (i.e. Bothrops, Agkistrodon, and 
Trimeresurus spp.) than between Lys-49 and Asp-49 proteins of the same species, 
indicating that the gene divergence occurred earlier than the separation of these genera 
(Francis et al., 1991). 
The first crystal structure of a Bothrops venom protein, B. asper myotoxin II, has been 
recently reported (Arni and Guti6rrez., 1993; Arni et al., 1995). As expected on the basis 
of the conserved architecture of PLA2s (Dijkstra et al., 1981; Renetseder et al., 1985; 
Westerlund et al., 1992), the three-dimensional structure of myotoxin II closely resembles 
that of Agkistrodon p. piscivorus Lys-49 PLA: (Holland et al., 1990; Scott et al., 1992), 
which shares over 75% sequence identity (Francis et al., 1991). However, in contrast o 
the latter, myotoxin II is dimeric, both in solution (Lomonte and Guti6rrez, 1989; Francis 
et al., 1991) and in the crystal state (Arni et al., 1995), and represents a novel dimeric form 
of PLA2. The two monomers in the asymmetric unit are related by a nearly perfect two-fold 
axis, but the dimer differs from that of Crotalus atrox PLA2 (Brunie et al., 1985) in that 
putative 'catalytic' sites are exposed to the solvent (Arni et al., 1995). When compared 
to Asp-49 catalytically-active PLA2s, myotoxin II has an altered local conformation i  the 
calcium-binding region, since the e-amino group of Lys-49 fills the site normally occupied 
by the calcium ion in Asp-49 enzymes (Arni et al., 1995). The crystal structure of myotoxin 
II will be important in future studies attempting to define the toxic site(s) of Bothrops 
myotoxins, o far explored on the basis of sequence comparisons (Francis et al., 1991) and 
molecular modelling (Lomonte et al., 1994e). 
Cloning 
Moura et al. (1993) reported the molecular cloning of a myotoxic PLA2 from B. 
jararacussu. With this powerful approach, in combination with site-directed mutagenesis 
and the growing crystallographic information, significant progress on the structure- 
function relationship of both crotalid (Moura et al., 1993; Ownby and Li, 1993) and elapid 
(Hodgson et al., 1993) PLA2 myotoxins is soon to be expected. 
NEUTRALIZATION AND ANTIGENIC RELATIONSHIPS 
Polyclonal and monoclonal ntibodies to Bothrops myotoxins have been useful to assess, 
by neutralization studies, the relative contribution of these toxins in the muscle-damaging 
activity of crude venoms; to determine the presence and antigenic relationships of 
myotoxins from different venoms; to study the structure-function relationship in myo- 
toxins; to visualize myotoxin binding to muscle sections in vitro; and to assess the 
distribution of myotoxins and antibodies in vivo, in animal models. 
Anti-myotoxin sera, and afffinity-purified polyclonal antibodies from antivenoms 
Monospeeific antibodies to myotoxins are readily purified from commercially available 
antivenoms by affinity chromatography on immobilized myotoxin columns. Equine 
antibodies to B. asper myotoxins I and II obtained by this means were utilized in 
neutralization studies to demonstrate that basic PLA2 myotoxins of this venom (all of them 
are cross-reactive when tested against polyclonal antibodies) are the main factors in the 
development ofmyonecrosis: preincubation ofcrude venom with antibodies to myotoxins 
I or II abolished 79 and 75%, respectively, of the muscle damage in mice (Lomonte t ai., 
1985, 1990c). This issue was also approached by raising antisera to purified B. asper 
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myotoxins I or II in rabbits: the monospecific antisera inhibited 70-80% of the venom 
myotoxic effect in preincubation experiments (Lomonte et al., 1987a; and unpublished 
results). In agreement with these findings, Moura et al. (1991b) showed that a mouse 
antiserum against B. jararacussu myotoxin (JSU-5, corresponding to bothropstoxins 
described by Homsi-Brandeburgo et al., 1988) neutralized virtually all the myotoxic effect 
of the homologous crude venom in preincubation tests. 
Anti-myotoxin polyclonal antibodies have revealed cross-reacting components in a 
variety of crude venoms from different species (Lomonte t al., 1985, 1987b, 1990a; Moura 
et al., 1990, 1991a, b). The conclusion emerging from these studies is that a 'family' of 
antigenically related myotoxic PLA2s occurs in many, although not all, Bothrops venoms. 
As a consequence, there is a high degree of cross-reactivity between different equine 
antivenoms to Bothrops pp. venoms produced in Latin America, regarding their ability 
to recognize these myotoxins in enzyme-immunoassays (Lomonte et al., 1991; and 
unpublished ata). Similar observations were made by preparing monospecific Bothrops 
antivenoms in mice (Moura et al., 1990). Moreover, several of these myotoxins cross-react 
with structurally related PLA2s from other crotalid genera, such as Trirneresurus and 
Agkistrodon spp. For example, T. flavoviridis basic protein I (Yoshizumi et al., 1990) and 
A. bilineatus basic PLA 2 1 (Nikai et al., 1993) are strongly recognized by rabbit antibodies 
to B. asper myotoxins I and II, by enzyme-immunoassay (cross-reactivities of 89 and 70%, 
respectively; unpublished observations by our group and Profs M. Ohno, University of 
Kyushu, and T. Nikai, University of Meijo, respectively). The conservation fat least some 
epitopes among several of these crotalid PLA2s is in agreement with their high sequence 
homology and similar three-dimensional structure. It would be of interest to assess whether 
the recognition of these cross-reactive epitopes by antibodies leads to an inhibition of toxic 
activities. 
Polyclonal antibodies to B. asper myotoxins were utilized to visualize toxin binding sites 
on frozen muscle sections exposed in vitro, by immunohistochemical staining. Both 
myotoxin I (Brenes et al., 1987) and II (Lomonte, unpublished data) can be visualized as 
a homogeneous staining pattern along the periphery of muscle fibres, with no evidence of 
binding to internal components of the cells. 
Monoclonal antibodies (MAbs) 
After the isolation of the first Bothrops myotoxin (Gutirrrez et aL, 1984a), the 
development of MAbs to this toxin provided unequivocal evidence for the presence of 
several major isoforms in the venom of B. asper (Lomonte and Kahan, 1988), now purified 
and referred to as myotoxins I-IV (Table 1). MAbs have been extremely valuable in 
neutralization studies, confirming earlier esults with polyclonal antibodies. Single neutral- 
izing MAbs, such as MAb-3 or MAb-4, abolished the muscle-damaging effect of the whole 
venom in preincubation experiments (Lomonte t al., 1992). In addition, MAbs to B. asper 
myotoxins were utilized in a quantitative enzyme-immunoassay to show the immediate 
in vivo disappearance of myotoxins from plasma, in a mouse model (Rovira et al., 1992). 
MAbs have also been useful in approaching the structure-function relationship of 
B. asper myotoxins. A clear dissociation between PLA: activity and myotoxic effect was 
observed when myotoxin I was neutralized with MAb-3 or MAb-4 (Lomonte t al., 1992). 
A precise mapping of the epitopes recognized by MAb-3 and MAb-4 could help to point 
out the molecular region involved in myotoxicity. These two MAbs recognize different-- 
perhaps overlapping--myotoxin epitopes, as suggested by their different patterns of 
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isoform recognition and competition binding data (Lomonte and Kahan, 1988). Unfortu- 
nately, their reactivity is lost upon antigen denaturation (Lomonte and Kahan, 1988; and 
unpublished ata), indicating the recognition of conformational, discontinuous epitopes. 
However, the neutralizing ability of these MAbs does not necessarily imply a recognition 
of the myotoxic site, as other well-known indirect neutralization mechanisms may occur 
(M~nez et al., 1992). Both neutralizing MAbs have the ability individually to form 
precipitable complexes with myotoxins, in contrast to non-neutralizing ones (Lomonte and 
Kahan, 1988). Thus, it remains to be determined whether monovalent Fab fragments of 
these neutralizing MAbs still retain their ability to inhibit myotoxins, in the absence of a 
macromolecular complex formation mechanism. 
Non-immunological neutralizing agents 
Despite the idea of utilizing heparin in the treatment of certain snakebites--aiming at 
the coagulation disorders--being old (Ahuja et al., 1946), it was shown only recently that 
heparin may be therapeutically useful against he myotoxicity of some venoms, being able 
to neutralize this effect (Melo and Suarez-Kurtz, 1988). Heparin, and other sulfated 
glycosaminoglycans and polyanions, have been shown to form complexes with PLA2 
myotoxins isolated from B. jararacussu (Melo et al., 1993) and B. asper (Lomonte t al., 
1994c) venoms, blocking their toxic activity when preincubated in vitro. The fact that these 
complexes are held, at least partially, by electrostatic forces, and that several types of 
glycosaminoglycans can bind (Melo et al., 1993; Lomonte et al., 1994c, e), suggests a
'non-specific' type of interaction. However, two observations raise the possibility that a 
specific recognition element might additionally be involved: first, not all structural types 
of highly basic myotoxins appear to be inhibited by heparin (Lomonte et al., 1994c). 
Second, the overall charge density of different glycosaminoglycans does not correlate with 
their myotoxin-binding ability. For example, the binding of chondroitin sulfate and 
dermatan sulfate to B. asper myotoxin II is weaker than the binding of heparan sulfate, 
although the latter is less sulfated (Lomonte et al., 1994e). 
The secreted non-pancreatic human PLA2, which has a similar molecular architecture 
and shares significant homology with crotalid class II PLA2s (Wery et al., 1991), was 
recently shown to interact with heparin in vitro, under physiological conditions (Dua and 
Cho, 1994). As both heparin (Ekre et al., 1992) and secreted PLA 2 (Pruzanski and Vadas, 
1991) are released uring inflammatory responses, their interaction is probably not 
fortuitous, but may have evolved as a physiological regulatory mechanism. 
The ability of heparin to neutralize the toxic actions of PLA2 myotoxins i independent 
of its anticoagulant activity (Lomonte t al., 1994c, e). This makes the non-anticoagulant 
forms of heparin (isolated by their low affinity for antithrombin, and comprising as much 
as two-thirds of conventional heparin preparations; Roden et al., 1992), attractive 
candidates for the in vivo neutralization ofmyotoxins. However, preliminary observations 
suggest hat, in vivo, high-affinity heparin-binding factors may compete strongly with 
myotoxins, thus affecting the neutralizing ability of heparin (Lomonte et al., 1994c). 
The blood serum of Clelia clelia, an ophiophagous colubrid snake distributed in Latin 
America, neutralizes the myotoxic activity of B. asper venom in mice (Lomonte et al., 
1982), and should therefore contain an inhibitor of its myotoxic PLA2s. This putative 
inhibitor(s) has not been purified yet. The blood sera of two marsupials, Didelphis 
marsupialis aurita and Philander oppossum, have also been shown to neutralize the 
myotoxic effect of B.jararacussu venom in vitro and in vivo (Melo and Suarez-Kurtz, 1988). 
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This serum factor is an ~-glycoprotein with acidic properties. An extract from the plant 
Eclipta prostrata is able to neutralize the myotoxic effect of Bothrops spp. (Melo et aL, 
1988) and of Crotalus durissus terrificus (Mors et al., 1989) venoms. In these studies, 
wedelolactone was identified as one of the active components of the plant extracts. 
PATHOGENESIS OF MUSCLE DAMAGE 
Bothrops myotoxins induce prominent muscle damage of rapid onset after i.m. injection. 
The pathogenesis of this effect has been investigated by following the morphological nd 
biochemical alterations in affected muscle. 
Macroscopic observations 
A few minutes after i.m. injection of myotoxins, mice have difficulties in moving the hind 
leg (Guti6rrez et al., 1989, 1991). After approximately 10 min there is a moderate swelling 
of the injected muscle, lasting for about 6 hr (Guti6rrez et al., 1989, 1991). No haemorrhage 
is observed in mice injected with myotoxins. 
Histological analysis 
The first morphological alterations induced by myotoxins in muscle fibres are focal, 
peripheral, wedge-shaped lesions which are observed as early as 15 min after injection 
(Guti6rrez et al., 1984a, b, 1989, 1991). These are identical to the 'delta lesions', originally 
described in Duchenne muscular dystrophy (Mokri and Engel, 1975), as well as in 
detergent-induced myonecrosis (Pestronk et al., 1982), which are focal areas of degener- 
ation located beneath portions of the cell where the plasma membrane is discontinuous 
or lost. After this initial alteration, there is a hypercontraction f myofibrils, with clumping 
of myofilaments (Guti6rrez et al., 1984a, b, 1989, 1990, 1991). Similar alterations have been 
described for other myotoxic agents present in snake venoms, such as for elapid 
cardiotoxins (Duchen et al., 1974; Ownby et al., 1993) and elapid PLA2s (Harris et al., 
1975; Harris and Maltin, 1982; Sharp et al., 1993), an indication that structurally different 
venom components can induce a similar pattern of pathological changes. Myonecrosis i  
widespread 3hr after injection of Bothrops myotoxins. In the case of myotoxin I from 
B. asper, between 3 and 6 hr there is a change in the morphological pattern of necrotic 
muscle fibres, as they shift from the clumped, hypercontracted pattern to a more hyaline 
pattern where myofibrillar material has a more uniform distribution (Guti6rrez et al., 
1984b, 1990). Inflammatory infiltrate, composed of polymorphonuclear leucocytes and 
macrophages, i  observed after the 6th hr and becomes abundant by 24--48 hr (Guti6rrez 
et al., 1984b, 1989, 1990, 1991). No histological alterations have been found in blood 
vessels or nerves after injection of these myotoxins (Guti6rrez et al., 1984b, 1989, 1991). 
lntravital microscopy 
The immediate stages of muscle damage induced by B. asper myotoxin II were analysed 
by intravital microscopy in the mouse cremaster muscle (Lomonte et al., 1994a). Muscle 
fibres exposed to myotoxin II respond within seconds with strong and slow contractions, 
which cause pronounced istortions of the local microvasculature, and cease in 1-2 min 
This phenomenon is compatible with the proposed action of Bothrops myotoxins at the 
plasma membrane level, causing a rapid calcium influx. Subsequently, 3-4 min after 
Phospholipase A 2Myotoxins from Bothrops 1413 
exposure, muscle fibres develop a narrow transverse band with local loss of striation, 
followed by a slow retraction of myofibrils in opposite directions until a transverse rupture 
of the fibre occurs. This phenomenon is repeated at several points along the muscle fibre, 
finally leaving rows of hypercontracted fibre fragments separated by spaces apparently 
devoid of myofilaments (Lomonte et al., 1994a). 
In addition to the effects on muscle fibres, the local oedema-inducing activity of 
myotoxin II (Lomonte and Guti6rrez, 1989; Lomonte et al., 1993) was confirmed 
intravitally, by visualizing a rapid leakage of fluoresceine-labelled d xtran marker from the 
muscle microvasculature, particularly at small venules and at their adjoining capillary 
segments (Lomonte et al., 1994a). 
Ultrastructural analysis 
The earliest alterations after i.m. injection of myotoxins from B. asper (Guti6rrez et al., 
1984b) and B. jararacussu (Guti6rrez et al., 1991) are focal disruptions or discontinuities 
at the plasma membrane. These focal lesions are also characterized by hypercontraction 
of myofilaments. Cells in more advanced degenerative stages are characterized by 
prominent hypercontraction f myofilaments, leaving cytosolic spaces apparently devoid 
of myofilaments. At later time periods, myofilaments shift to a more uniform pattern of 
distribution, o longer showing aclumped appearance (Guti6rrez et al., 1984b, 1990, 1991). 
Necrotic cells exhibit conspicuous alterations in all organelles. Mitochondria show 
high-amplitude swelling, dense intracrystal spaces, flocculent densities and vesiculated 
cristae. In some of them the membranes are disrupted (Guti6rrez et al., 1984b, 1991). A 
large population of small vesicles appears in necrotic ells, probably as a consequence of 
intracellular membrane alterations, since no sarcoplasmic reticulum or T tubules are 
observed. Moreover, B. asper myotoxin I inhibits calcium-ATPase activity of rabbit 
sarcoplasmic reticulum and hydrolyses phospholipids of this organelle (Guti6rrez et al., 
1987). Necrotic fbres show myonuclei with clumped chromatin and disrupted membranes. 
Throughout the process of necrosis, the basal lamina remains apparently intact at the 
periphery of the cells. However, there may be changes in specific basal amina components, 
such as those reported in other muscle pathologies (Gulati et al., 1983; Gulati, 1985). 
Polymorphonuclear leucocytes and macrophages are abundant after the 6th hr, both in the 
interstitial space and inside necrotic fibres (Guti6rrez et al., 1984b, 
Biochemical alterations 
A prominent increase in plasma creatine kinase levels is observed after injection of 
Bothrops myotoxins (Guti6rrez et al., 1984a, 1989, 1991; Lomonte and Guti6rrez, 1989; 
Lomonte t al., 1990b; Moura et al., 1990, 1991b; Diaz et al., 1992). Creatine kinase levels 
peak between 1 and 3 hr, decreasing afterwards. Simultaneously, there is a reduction in 
creatine content and creatine kinase activity in the injected gastrocnemius, but not in the 
contralateral muscle (Moreno and Guti6rrez, 1988). An increment inmuscle calcium levels 
occurs after administration of B. asper myotoxin I (Guti6rrez et al., 1984a) and 
B. nummifer myotoxin (Guti6rrez et al., 1989). 
Changes in myofibrillar proteins after injection of B. asper myotoxin I were studied by 
Guti6rrez et al. (1990). The initial stage of hypercontraction is ot associated with drastic 
myofilament degradation, with the exception of desmin, which disappears as early as 
15 min after injection. After the 3rd hr, myofilaments shift from a hypercontracted to a 
hyaline pattern, a change associated with the removal of ~-actinin. Finally, at later time 
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periods, there is a widespread egradation of all myofibrillar proteins, probably as a 
consequence of the activity of proteases from inflammatory phagocytic cells. 
Histological, ultrastructural and biochemical evidence strongly indicate that muscle cell 
plasma membrane is the first cellular structure to be affected by Bothrops myotoxins. 
Immunohistochemical st ining of muscle sections exposed to B. asper myotoxins I (Brenes 
et aL, 1987) and II (Lomonte, unpublished results) in vitro showed the binding of these 
toxins only at the periphery of muscle cells. 
Skeletal muscle regeneration 
Muscle regeneration after myonecrosis induced by B. asper myotoxin I (Gutirrrez et al., 
1984c), bothropstoxins I and II from B. jararacussu (Homsi-Brandeburgo et al., 1988; 
Gutirrrez et al., 1991) and B. nummifer myotoxin (Gutirrrez et al., 1989) proceeds normally 
and successfully. Small regenerating muscle cells, with centrally located nuclei, are 
observed 1week after injection. By 28 days, the regenerative process is complete, as the 
diameter of regenerating muscle fibres does not differ from the diameter of adult normal 
muscle fibres, although regenerating cells still have centrally located nuclei. Nerves and 
blood vessels remain intact throughout the process of regeneration and no fibrosis or 
proliferation of fibroblasts is observed. Very similar findings have been described with 
other myotoxic PLA2s isolated from elapid snake venoms, such as notexin (Harris et al., 
1975) and taipoxin (Maltin et aL, 1983). It was proposed that the regenerative process is 
adequate because myotoxins do not affect blood vessels or nerves, and the basal lamina 
remains at the periphery of necrotic ells (Gutirrrez et al., 1984c, 1989, 1991), playing the 
role of a scaffold for muscle regeneration (Vracko and Benditt, 1972). 
In contrast to the observations described, muscle regeneration after injection of crude 
venoms with myotoxic and haemorrhagic a tivities is severely impaired (Gutirrrez et al., 
1984c; Queiroz et al., 1984; Arce et al., 1991). In these cases there is abundant fibroblast 
proliferation and fibrosis, and regenerating fibres are of a very small diameter. It was 
suggested that the drastic microvascular lterations induced by haemorrhagic toxins are 
responsible for the poor regeneration, asan adequate blood supply is a key condition for 
muscle regeneration (Allbrook, 1981; Grounds, 1991). 
STUDIES ON THE MECHANISM OF ACTION 
Effects on liposomes 
Liposomes are useful models for studying the interaction of cytolysins with membranes. 
Various studies have demonstrated that Bothrops myotoxins disrupt multilamellar and 
unilamellar vesicles, releasing entrapped enzymatic or fluorescent markers (Diaz et al., 
1991; Rufini et al., 1992). Electron-spin resonance measurement of intravesicular 
TEMPOcholine reduction by external ascorbate was also used to monitor liposome 
leakage (Rufini et al., 1992). Negatively charged multilamellar liposomes are affected by 
these myotoxins, whereas no effect is observed on positively charged vesicles (Diaz et aL, 
1991; Bultrbn et al., 1993a). Unilamellar vesicles made of phosphatidylcholine and 
phosphatidic acid are more susceptible to B. asper myotoxin II than vesicles made only 
of phosphatidylcholine (Rufini et al., 1992). These studies indicate that Bothrops myotoxins 
affect preferentially negatively charged bilayers, suggesting the involvement ofbasic amino 
acids in the course of the membrane-perturbing mechanism, perhaps in the binding step. 
Interestingly, liposome disruption by B. asper myotoxin III is inhibited at 4°C (Bultr6n 
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et al., 1993a), suggesting that membrane fluidity is an important factor in the mechanism 
of action. 
The liposome-disrupting effect of two myotoxins which lack PLA2 activity (B. asper 
myotoxin II and B. moojeni myotoxin II) is not affected when the assay is performed in 
the absence of calcium, and hence of enzymatic activity (Diaz et al., 1991; Rufini et al., 
1992). In contrast, the liposome-disrupting effect of two enzymatically active myotoxins 
(B. asper myotoxin I and B. atrox myotoxin) is significantly decreased, although not 
completely abolished, by elimination of calcium (Diaz et al., 1991). These results uggest 
that Bothrops myotoxins are capable of disrupting bilayers by a mechanism independent 
of enzymatic phospholipid hydrolysis, and that PLA2 activity in enzymatically active 
variants enhances liposome disruption. Pedersen et al. (1994) clearly confirmed this 
hypothesis, by demonstrating that B. asper myotoxin II causes rapid membrane l akage 
of liposomes made of non-hydrolysable ether-linked phospholipids. 
Effects on muscle preparations in vitro 
When B. asper myotoxins I and III, B. nummifer myotoxin, and B. jararacussu 
bothropstoxin are incubated with mouse gastrocnemius and extensor digitorum longus 
muscles, a dose-dependent release of creatine kinase occurs, indicating a membrane- 
disrupting activity (Guti~rrez et al., 1986a, b; Melo et al., 1993; Bultr6n et al., 1993a). In 
the case of B. asper myotoxin III, membrane damage is inhibited if the muscles are 
incubated at 4°C (Bultr6n et al., 1993a). When calcium is eliminated and EDTA added 
to the bathing solution, there is a significant reduction in creatine kinase release induced 
by B. asper myotoxin III, although a residual myotoxicity is observed (Bultr6n et al., 
1993a). In contrast, here is no reduction in myotoxic activity when enzymatically inactive 
B. nummifer myotoxin is incubated in the absence of calcium (Guti~rrez et al., 1986b). 
Bothrops jararacussu bothropstoxin I inhibits muscle twitch tension evoked either 
directly or indirectly through stimulation of the motor nerve in the mouse phrenic 
nerve-diaphragm preparation (Heluany et al., 1992). Moreover, the toxin induces 
membrane depolarization, which is inhibited in the presence of 10mM Ca 2÷, and 
contracture (Heluany et al., 1992). 
Effects on cells in culture 
Despite the observation that Bothrops myotoxins eem to affect only skeletal muscle 
in vivo (Guti&rez et al., 1986a; Moreno and Guti~rrez, 1988), studies with cultured cells 
clearly indicate that they affect not only myoblasts and myotubes, but also other cell types. 
Myotoxins from B. nummifer are cytotoxic for cultured muscle cells, neurones, macro- 
phages and fibroblasts, although they are more active towards myotubes (Brus~s et al., 
1993). Moreover, B. asper myotoxins II (Lomonte et al., 1994d) and III (Bultr6n et al., 
1993b) induce membrane damage in a variety of cell types in culture. Cytotoxicity ishigher 
if cells are incubated in solutions devoid of calcium, decreasing when calcium is added 
(Bultr6n et al., 1993b). Similar observations have been made with other membrane-dis- 
rupting agents (Bashford et al., 1986). It has been observed that divalent cations protect 
cells against he action of a variety of cytolytic agents (Bashford et al., 1989). As in the 
case of liposomes, myotoxins II and III lack cytotoxicity at 4°C, suggesting that this effect 
is influenced by membrane fluidity (Bultr6n et al., 1993b; Lomonte t al., 1994d). The only 
cells that appear to be resistant to the membrane-damaging activity of B. asper myotoxins 
I, II, and III are erythrocytes from several species (Guti6rrez et al., 1986a; Bultr6n et al., 
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1993b; Gen6, unpublished results), despite that myotoxin II has been reported to bind 
mouse erythrocytes (Rovira et al., 1992). 
These studies clearly indicate that at least some Bothrops myotoxins affect in vitro many 
cell types in addition to skeletal muscle myoblasts, thus behaving more as cytotoxins than 
as myotoxins. Nevertheless, cultured myotubes are more susceptible than myoblasts to 
B. asper myotoxins I and II (V. Arce, personal communication), suggesting that the 
observed specificity of myotoxins for skeletal muscle in vivo may be due to a much higher 
susceptibility of mature muscle cells as compared to other cell types. 
Since B. asper myotoxin II does not damage target cells at 4°C, Lomonte t al. (1994d) 
showed that washing with cold culture medium easily removed the toxin from cells, 
resulting in a loss of cytolytic effect when cultures were subsequently transferred to 37°C. 
Moreover, even after 30 min of incubation with cells at 4°C, myotoxin II was still 
susceptible to neutralization by a monoclonal antibody (MAb-3) or by heparin with low 
affinity for antithrombin. These results indicate that the strength of interaction of 
myotoxin II with its putative membrane target is greatly diminished at 4°C, and suggest 
that in addition to an electrostatic nteraction, hydrophobic penetration is probably 
required in the cytolytic mechanism (Lomonte et al., 1994d). 
The broad cytolytic specificity of Bothrops myotoxins evaluated so far is in contrast to 
the lack of in vitro cytolytic activity of basic PLA2 myotoxins isolated from Notechis s. 
scutatus (notexin) and Vipera russelli venoms (Lomonte et al., 1994d), suggesting that 
different molecular pathways of muscle damage caused by PLA 2 myotoxins might exist. 
Other pharmacological activities 
Lethal activity has been reported for B. nummifer myotoxin, B. asper myotoxin I, B. 
godmani myotoxin II, and B. jararacussu bothropstoxin I, with i.v. LDs0S of 3.9, 5.6, 4.2, 
and 4.8 mg/kg, respectively (Guti6rrez et al., 1986a, b; Homsi-Brandeburgo et al., 1988; 
Diaz et al., 1992) In addition, B. asper myotoxin I has an intraventricular LDs0 of 
0.025 mg/kg (Guti6rrez et al., 1986a) and bothropstoxin I has an i.p. LDs0 of 7.5 mg/kg 
(Homsi-Brandeburgo et al., 1988). Thus, Bothrops myotoxins have low toxicity when tested 
by the i.v. route. This is in contrast o other myotoxic PLA2s from elapid and viperid 
venoms, which are neurotoxic and highly lethal (Rosenberg, 1990). 
Bothrops myotoxins induce oedema in the mouse footpad assay (Guti6rrez et al., 1986a, 
b; Lomonte and Guti6rrez, 1989; Lomonte t al., 1993, 1994c; Diaz et al., 1992). Oedema 
induced by B. asper myotoxins I (Guti6rrez et al., 1986a) and II (Lomonte t al., 1993) 
is of rapid onset, reaching its peak by 1 hr and remaining high for several hours. The early 
oedema (30m in) is inhibited by pretreatment with cyproheptadine, indicating that 
histamine and/or serotonin are involved. The late oedema (5 hr) is inhibited by pretreat- 
ment with aspirin, suggesting the participation of prostaglandins (Guti6rrez et aL, 1986a). 
Although the oedema-inducing effect of PLA2s has usually been attributed to their ability 
to hydrolyse phospholipids (Cirino et aL, 1989; Vishwanath et aL, 1988; Lloret and 
Moreno, 1993), the finding that B. asper myotoxin II can induce oedema in the absence 
of PLA2 activity (Lomonte t al., 1993, 1994a) implies a different mechanism ofaction for 
this pharmacological effect. An indirect oedema response to muscle damage seems unlikely, 
since there are highly myotoxic venoms (e.g. from several Micrurus spp.) that do not induce 
significant oedema (Guti6rrez et al., 1983) in the mouse. The possible direct action of 
myotoxin II on endothelial cells or tissue mast cells has been speculatively suggested 
(Lomonte et al., 1994b, c). Bothrops asper myotoxin II also induces a rapid systemic 
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interleukin-6 response in mice, presumably as an indirect consequence of muscle necrosis 
(Lomonte et al., 1993), leading to an acute-phase r sponse. 
All the enzymaticaUy active variants of myotoxins are anticoagulant in vitro, prolonging 
recalcification time of platelet-poor plasma. In contrast, Bothrops myotoxins that lack 
PLA2 activity fail to induce anticoagulation (Guti6rrez et al., 1986a, b; Lomonte and 
Guti6rrez, 1989; Lomonte t al., 1990b; Kaiser et al., 1990; Diaz et al., 1992) The addition 
of phosphatidylserine prevents the anticoagulant effect of B. godmani myotoxin I, 
suggesting that anticoagulation might be due to an interference with the role of 
phospholipids involved in the coagulation cascade. The fact that only enzymatically active 
variants induce this effect strongly suggests that phospholipid hydrolysis is required for 
anticoagulation (Diaz et al., 1991, 1992). In vivo, B. asper myotoxin I does not prolong 
clotting time (Alvarado and Guti6rrez, 1988), indicating that myotoxins are not involved 
in the haemostatic alterations observed in Bothrops envenomations. 
Structure-function relationships 
Kini and Iwanaga (1986) proposed that a cationic site around residues 79-87 is 
responsible for myotoxicity in presynaptic PLA2 neurotoxins with myotoxic activity. Such 
a cationic site is not present in B. asper myotoxins II (Francis et al., 1991) and III (Kaiser 
et al., 1990), and B. jararacussu bothropstoxin I (Cintra et al., 1993). When sequences of 
myotoxic and non-myotoxic PLA2s are compared, the following amino acids are present 
in several myotoxic variants: Lys-38, Thr-112 and Tyr-ll3, in addition to three or four 
tyrosines between residues 112 and 121 (Francis et al., 1991). In the three-dimensional 
structure of B. asper myotoxin II, Lys-38 lies close to the C-terminus (Arni et al., 1995). 
Interestingly, the C-terminal region has been recently implicated in the cytolytic activity 
of B. asper myotoxin II (Lomonte et al., 1994e). 
Treatment of B. asper myotoxin II with cyanogen bromide releases its N-terminal 
octapeptide, resulting in the reduction of myotoxicity and liposome-disrupting activities 
(Diaz et al., 1994a). A similar decrease in cytotoxicity after cyanogen bromide digestion 
was observed in the case of nigexin, a toxic PLA2 from Naja nigricollis venom (Chwetzoff, 
1990). The N-terminal domain in PLA2s participates in the interfacial binding surface 
(Scott et al., 1990), a region involved in the interaction with micellar substrates. Therefore, 
the observations made with B. asper myotoxin II may indicate that the N-terminal region 
plays a role in myotoxicity. Alternatively, such treatment may induce conformational 
changes affecting other regions of the molecule (Diaz et al., 1994a). 
Alkylation of B. asper myotoxin III with p-bromophenacyl bromide (BPB) reduces 
enzymatic activity by more than 95%, whereas the membrane-damaging effect on 
myoblasts was reduced by 70% (Bultr6n et al., 1993b), suggesting a dissociation of both 
activities. BPB modification of enzymaticaUy inactive B. asper myotoxin II reduces its 
myotoxic and liposome-disrupting activities (Diaz et al., 1993). This suggests that, in 
addition to the covalent modification of histidine, there may be conformational changes 
affecting pharmacological activities. Renetseder t al. (1988) described alterations in the 
crystal structure of a PLA2 as a consequence of BPB modification. 
Molecular analyses of the interaction between heparin and B. asper myotoxin II 
provided valuable insights on the structure-function relationships of this protein. In 
contrast to neutralizing MAbs (see Monoclonal antibodies, p. 1410), heparin was found to 
interact with a continuous tretch of amino acids, near the C-terminus of myotoxin II 
(Lomonte t al., 1994e). This lysine-rich eparin-binding region includes residues 115-129 
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(numbering of Renetseder t al., 1985), and is clearly separated from the 'catalytic' site 
(Scott et al., 1990). Molecular modelling studies revealed that two lysine residues, Lys-36 
and Lys-38, come in close vicinity to this region in the native structure of the protein (Arni 
et al., 1995), enhancing its cationic haracter and, presumably, its heparin-binding ability 
(Lomonte et al., 1994e). Interestingly, a synthetic peptide of residues 115-129 was able 
specifically to reproduce the cytolytic effect of myotoxin II on cultured cells, although with 
a 10--15-fold lower efficiency than the whole protein. The data support he conclusion that 
heparins neutralize myotoxin II by binding to a region directly involved in its cytolytic 
activity, providing the first experimental evidence of a cytotoxic region in a myotoxic PLA2 
(Lomonte t al., 1994e). However, the role of this molecular region in myotoxicity remains 
to be investigated. While this putative cytotoxic region of myotoxin II is different from 
that predicted by Kini and Iwanaga (1986), it is of interest o note that it forms a 
hydrophobic/cationic combination, a structural feature that seems to be common to many 
cytotoxins (Kini and Evans, 1989; Bilwes et al., 1994; Chien et al., 1994). 
Neutralization studies using heparins have also confirmed the dissociation of enzymatic 
and myotoxic activities of B. asper myotoxin III: myotoxicity was inhibited whereas PLA2 
activity was not affected (Lomonte et al., 1994c). This observation is in agreement with 
the hypothesis that proposes the existence of a cytolytic toxin region distinct from the 
catalytic site. 
Bothrops asper myotoxin II was found to undergo autocatalytic acylation, binding 
covalently long-chain fatty acids after in vitro incubation (Pedersen et al., 1995). Acylated 
myotoxin binds to the surface of unilamellar liposomes, with the fatty acid moiety inserted 
into the lipid bilayer. Thus fatty acids may play a role as an anchor in the membrane and, 
perhaps, participating in the membrane perturbation induced by these myotoxins, a
hypothesis that needs to be tested. Lugtigheid et al. (1993) recently demonstrated that 
acylation of porcine pancreatic PLA2 influences its monolayer penetrating ability. 
There is no information on the presence of membrane r ceptors for Bothrops myotoxic 
PLA2s. The observation that negatively charged, but not positively charged, liposomes are 
disrupted by Bothrops myotoxins suggests that negatively charged phospholipids may play 
a role in the binding of these myotoxins to membranes (Diaz et al., 1991; Rufini et al., 
1992). It would be relevant to study whether cell susceptibility correlates with the amount 
of negatively charged phospholipids present in the outer monolayer of plasma membranes. 
In an attempt to define whether anionic acceptor sites, different from phospholipids, play 
a role in the cytolytic mechanism of B. asper myotoxin II, cells were pretreated with 
neuraminidase, heparitinase, tunicamycin, and protamine, and subsequently assayed for 
cytotoxicity. However, none of these treatments modified the susceptibility of cells to the 
toxin, indicating that its action is not affected by removal of sialic acid or cell surface 
heparan sulfate, by inhibition of N-glycosylation of proteins, or by the presence of 
high concentration f protamine, a polycationic peptide, in the medium (Lomonte t al., 
1994c, d). 
Lambeau et al. (1990, 1994) have purified, cloned and characterized a receptor for elapid 
PLA2s from the membrane of muscle cells. It is a membrane protein of 180,000 mol. wt, 
with an N-terminal cysteine-rich domain, a fibronectin type II domain, eight repeats of a 
carbohydrate r cognition domain, a transmembrane domain and an intracellular C-termi- 
nal domain (Lambeau et al., 1994). It would be important to study whether this receptor 
participates in the interaction between Bothrops myotoxins and muscle plasma membrane. 
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CONCLUDING REMARKS: A WORKING HYPOTHESIS ON THE MECHANISM OF ACTION 
The data collected on the effect of Bothrops myotoxins on cells, liposomes, and skeletal 
muscle in vivo may be unified in the following hypothetical mechanism of action: 
myotoxins bind to a still unidentified site in the muscle cell plasma membrane. This site 
may be a protein, such as the receptor characterized by Lambeau et al. (1994), a negatively 
charged phospholipid omain, or another type of membrane component. In any case, an 
electrostatic interaction between cationic sites of the toxins and negatively charged groups 
in the membrane seems to be involved. After this initial binding, myotoxins penetrate the 
bilayer by a hydrophobic interaction mediated by a cytotoxic region of the molecule, 
different from the catalytic site. It is suggested that this region combines basic and 
hydrophobic amino acid residues, such as the proposed cytolytic region of B. asper 
myotoxin II (Lomonte et al., 1994e). In addition, acylation may contribute to the 
interaction and penetration of the cell membrane. Such hypothetical toxic domain would 
be present in both enzymatically active and inactive variants, although it may not be 
structurally identical in all myotoxins of this group. It is very likely, however, that the 
presence of hydrophobic residues flanked by cationic residues constitutes a common 
molecular design for the cytolytic region in these myotoxins. The penetration of this region 
in the hydrophobic ore of the bilayer is responsible for membrane destabilization, with 
the consequent impairment in the regulation of the permeability to ions and macromol- 
ecules. Membrane penetration probably requires a fluid membrane, as myotoxins fail to 
induce cytotoxicity at 4°C. Besides this initial membrane perturbation, enzymatically active 
variants induce further membrane damage by hydrolysing bilayer phospholipids, an effect 
not observed with Lys-49 enzymatically inactive myotoxins. A prominent calcium influx 
is probably the most relevant consequence of membrane disturbance, being responsible for 
the onset of a variety of degenerative mechanisms uch as cytoskeletal alterations 
(e.g myofilament hypercontraction), mitochondrial damage, and activation of calcium- 
dependent proteases and phospholipases which, in turn, cause further cell damage. 
Although some progress has been made towards understanding the structure and 
mechanism of action of Bothrops myotoxins, our knowledge is still fragmentary. It is 
expected that new findings will provide a more clear picture on the way these toxins bind 
and interfere with membrane homeostasis, as well as on their structure-function relation- 
ships. Hopefully, such knowledge will reveal mechanisms of cellular damage relevant for 
muscle pathology in addition to snakebite, paving the way for the development of more 
efficient herapeutic strategies. 
Acknowledgements--The important contributions bydifferent collaborators and graduate students othe studies 
on myotoxins are gratefully acknowledged, as well as the financial support from Vicerrectoria deIn~,,estigaci6n 
(Universidad de Costa Rica), International Foundation for Science, Third World Academy of Sciences, Swedish 
Agency for Research Cooperation with Developing Countries--SAREC, and Costa Rican National Council for 
Scientific and Technological Research (CONICIT). 
REFERENCES 
Ahuja, M. L., Veeraraghavan, N. and Menon, I. G. K. (1946) Action of heparin on the venom of Echis carinatus. 
Nature 158, 878. 
Ailbrook, D, (1981) Skeletal muscle regeneration. Muscle Nerve 4, 234-245. 
Alvarado, J. and Guti~rrez, J. M. 0988) Anticoagulant effect of myotoxic phospholipase A 2isolated from the 
venom of the snake Bothrops usper (Viperidae). Rev. Biol. Trop. 36, 563-565. 
TOX 33/|1~C 
1420 J .M. GUTII~RREZ and B. LOMONTE 
Arce, V., Brenes, F. and Gutirrrez, J. M. (1991) Degenerative and regenerative changes in murine skeletal muscle 
after injection of venom from the snake Bothrops asper: a histochemical nd immunocytochemical study. Int. 
J. exp. Path. 72, 211-226. 
Arni, R. K. and Gutirrrez, J. M. (1993) Crystallization and preliminary diffraction data of two myotoxins i olated 
from the venoms ofBothrops asper (terciopelo) and Bothrops nummifer (jumping viper). Toxican 31, 1061-1064. 
Arni, R. K., Ward, R. J., Gutirrrez, J. M. and Tulinsky, A. (1995) Crystal structure of a calcium-independent 
phospholipase-like myotoxic protein from Bothrops asper venom. Acta Crystallographica 1)51, 311-317. 
Bashford, C. L., Alder, G. M., Menestrina, G., Micklem, K. J., Murphy, J. J. and Pasternak, C. A. (1986) 
Membrane damage by hemolytic viruses, toxins, complement, and other cytotoxic agents. J. biol. Chem. 261, 
9300-9308. 
Bashford, C. L., Rodrigues, L. and Pasternak, C. A. (1989) Protection of cells against membrane damage by 
haemolytic agents: divalent cations and protons act at the extracellular side of the plasma membrane. Biochim. 
biophys. Acta 983, 56-64. 
Bilwes, A., Rees, B., Moras, D., Mrnez, R. and M~nez, A. (1994) X-ray structure at 1.55 A of toxin 3,, a 
cardiotoxin from Naja nigricollis venom. Crystal packing reveals a model for insertion into membranes. 
J. molec, biol. 239, 122-136. 
Bolafios, R. (1982) Las serpientes venenosas de Centroamrrica y el problema del ofidismo. Primera parte: 
aspectos zool6gicos, epidemiol6gicos y biomedicos. Rev. Cost. Cienc. M~d. 3, 165-184. 
Brenes, F., Guti&rez, J. M. and Lomonte, B. (1987) Immunohistoehemical demonstration of the binding of 
Bothrops asper myotoxin to skeletal muscle sarcolemma. Toxicon 25, 574-577. 
Brunie, S., Bolin, J., Gewirth, D. and Sigler, P. B. (1985) The refined crystal structure of dimeric phospholipase 
A2 at 2.5 A. Access to a shielded catalytic enter. J. biol. Chem. 260, 9742-9749. 
Brusrs, J. L., Capaso, J., Katz, E. and Pilar, G. (1993) Specific in vitro biological activity of snake venom 
myotoxins. J Neurochem. 60, 1030-1042. 
Bultr6n, E., Guti~rrez, J. M. and Thelestam, M. (1993a) Effects of Bothrops asper (terciopelo) myotoxin III, a 
basic phospholipase A2, on liposomes and mouse gastrocnemius muscle. Toxicon 31, 217-222. 
Bultr6n, E., Thelestam, M. and Gutirrrez, J. M. (1993b) Effects on cultured mammalian cells of myotoxin III, 
a phospholipase A 2 isolated from Bothrops asper (terciopelo) venom. Biochim. biophys. Acta 1179, 253-259. 
Chien, K. Y., Chiang, C. M., Hseu, Y. C., Vyas, A. A., Rule, G. S. and Wu, W. G. (1994) Two distinct ypes 
of cardiotoxin as revealed by the structure and activity relationship of their interaction with zwitterionic 
phospholipid ispersions. J. biol. Chem. 269, 14,473-14,483. 
Cho, W., Tomasselli, A., Heinrikson, R. L. and Kezdy, F. J. (1988) The chemical basis for interfacial activation 
of monomeric phospholipases A:. J. biol. Chem. 263, 11,237-I 1,241. 
Chwetzoff, S. (1990) On the mode of action of basic phospholipase A 2 from Naja nigricollis venom. Biochim. 
biophys. Acta 1045, 285-290. 
Cintra, A. C. O., Marangoni, S., Oliveira, B. and Giglio, J. R. (1993) Bothropstoxin-I: amino acid sequence and 
function. J. Prot. Chem. 12, 57-64. 
Cirino, G., Peers, S. H., Wallace, J. L. and Flower, R. J. (1989) A study of phospholipase A2-induced oedema 
in rat paw. Eur. J. Pharmac. 166, 505-510. 
Davidson, F. and Dennis, E. A. (1990) Evolutionary relationships and implications for the regulation of 
phospholipase A: from snake venom to human secreted forms. J. molec. EvoL 31, 228-238. 
Diaz, C., Gutirrrez, J. M., Lomonte, B. and Gene, J. A. (1991) The effect of myotoxins isolated from Bothrops 
snake venoms on multilameUar liposomes: relationship to phospholipase A2, anticoagulant and myotoxic 
activities. Biochim. biophys. Acta 1070, 455-460. 
Diaz, C., Guti~rrez, J. M. and Lomonte, B. (1992) Isolation and characterization f basic myotoxic phospho- 
lipases A 2 from Bothrops godmani (Godman's pit viper) snake venom. Arch. Biochem. Biophys. 298, 135-142. 
Diaz, C., Guti&rez, J. M., Lomonte, B. and Nufiez, J. (1993)p-Bromophenacyl bromide modification of Bothrops 
asper myotoxin II, a lysine-49 phospholipase A2, affects its pharmacological activities. Toxicon 31, 1202-1206. 
Diaz, C., Alape, A., Lomonte, B., Olamendi, T. and Gutirrrez, J. M. (1994) Cleavage of the NH2-terminal 
octapeptide of Bothrops asper myotoxic lysine-49 phospholipase A2 reduces its membrane-destabilizing effect. 
Arch. Biochem. Biophys. 312, 336-339. 
Diaz, C., Lomonte, B., Zamudio, F. and Guti~rrez, J. M. (1995) Purification and characterization f myotoxin 
IV, a phospholipase A2 variant, from Bothrops asper snake venom. Natural Toxins 3, 26-31. 
Dijkstra, B. W., Kalk, K. H., Hol, W. G. and Drenth, J. (1981) Structure of bovine pancreatic phospholipase 
A 2 at 1.7 A, resolution. J molec. Biol. 147, 97-123. 
Dua, R. and Cho, W. (1994) Inhibition of human secretory class II phospholipase A e by heparin. Eur. J. Biochem. 
221, 481-490. 
Duchen, L. W., Excell, B. J., Patel, R. and Smith, B. (1974) Changes in motor endplates resulting from muscle 
fibre necrosis and regeneration. A light and electron microscopic study of the effects of the depolarizing fraction 
(cardiotoxin) of Dendroaspis jamesoni venom. J. neurol. Sci. 21, 391-417. 
Ekre, H. P., Naparstek, Y., Lider, O., Hyden, P., H/igermark, 0., Nilsson, T., Vlodavsky, I. and Cohen, I. (1992) 
Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and of lymphocyte 
migration. In: Heparin and Related Polysaccharides, pp. 329-340 (Lane, D. A., Bj6rk, I. and Lindahl, U., Eds). 
New York: Plenum Press. 
Phospholipase A2 Myotoxins from Bothrops 1421 
Faure, G. and Bon, C. (1987) Several isoforms of crotoxin are present in individual venoms from the South 
American rattlesnake Crotalus durissus terrificus. Toxicon 25, 229-234. 
Francis, B., Gutirrrez, J. M., Lomonte, B. and Kaiser, I. I. (1991) Myotoxin II from Bothrops asper (terciopelo) 
venom is a lysine-49 phospholipase A2 Arch. Biochem. Biophys. 284, 352-359. 
Fukagawa, T., Nose, T., Shimohigashi, Y., Ogawa, T., Oda, N., Nakashima, K., Chang, C. and Ohno, M. (1993) 
Purification, sequencing and characterization f single amino acid-substituted phospholipase A 2 isozymes from 
Trimeresurus gramineus (green habu snake) venom. Toxicon 31, 957-967. 
Grounds, M. D. (1991) Towards understanding skeletal muscle regeneration. Path. Res. Pract. 187, 1-22. 
Gulati, A. K. (1985) Basement membrane component changes in skeletal muscle transplants undergoing 
regeneration or rejection. J cell. Biochern. 27, 337-346. 
Gulati, A. K., Reddi, A. H. and Zalewski, A. A. (1983) Changes in the basement membrane zone components 
during skeletal muscle fiber degeneration and regeneration. J. Cell Biol. 97, 957-962. 
Gutirrrez, J. M., Lomonte, B., Portilla, E., Cerdas, L. and Rojas, E. (1983) Local effects induced by coral snakes 
(Micrurus) venoms: evidence of myonecrosis after experimental inoculation of venom from five species. 
Toxicon 21, 777-783. 
Gutirrrez, J. M., Ownby, C. L. and Odell, G. V. (1984a) Isolation of a myotoxin from Bothrops asper venom: 
partial characterization a d action on skeletal muscle. Toxicon 22, 115-128. 
Gutirrrez, J. M., Ownby, C. L. and OdeU, G. V. (1984b) Pathogenesis of myonecrosis induced by crude venom 
and a myotoxin of Bothrops asper. Exp. molec. Path. 40, 367-379. 
Gutirrrez, J. M., Ownby, C. L. and Odell, G. V. (1984c) Skeletal muscle regeneration after myonecrosis induced 
by crude venom and a myotoxin from the snake Bothrops asper (fer-de-lance). Toxicon 22, 719-731. 
Gutirrrez, J. M., Lomonte, B., Chaves, F., Moreno, E. and Cerdas, L. (1986a) Pharmacological ctivities of a 
toxic phospholipase A isolated from the venom of the snake Bothrops asper. Comp. Biochem. Physiol. 84C, 
159-164. 
Gutirrrez, J. M., Lomonte, B. and Cerdas, L. (1986b) Isolation and partial characterization f a myotoxin from 
the venom of the snake Bothrops nummifer. Toxicon 24, 885-894. 
Gutirrrez, J. M., Rojas, G., Lomonte, B., Genr, J. A. and Cerdas, L. (1987) Effects of a myotoxic phospholipase 
A2 isolated from Bothrops asper venom on skeletal muscle sarcoplasmic reticulum. Toxicon 25, 1244-1248. 
Gutirrrez, J. M., Chaves, F., Genr, J. A., Lomonte, B., Camacho, Z. and Sehosinsky, K. (1989) Myonecrosis 
induced by a basic myotoxin isolated from the venom of the snake Bothrops nummifer (jumping viper) from 
Costa Rica. Toxicon 27, 735-746. 
Gutirrrez, J. M., Arce, V., Brenes, F. and Chaves, F. (1990) Changes in myofibrillar components after skeletal 
muscle necrosis induced by a myotoxin isolated from the venom of the snake Bothrops asper. Exp. molec. Path. 
52, 25-36. 
Gutirrrez, J. M., Nufiez, J., Diaz, C., Cintra, A. C. O., Homsi-Brandeburgo, M. I. and Gigiio, J. R. (1991) 
Skeletal muscle degeneration a d regeneration after injection of bothropstoxin II, a phospholipase A 2 isolated 
from the venom of the snake Bothrops jararacussu. Exp. molec. Path. 55, 217-229. 
Harris, J. B. (1991) Phospholipases in snake venoms and their effects on nerve and muscle. In: Snake Toxins 
pp. 91-129 (Harvey, A. L., Ed.). New York: Pergamon Press. 
Harris, J. B. (1992) Natural toxins in study of degeneration and regeneration of skeletal muscle. In: Methods 
in Neurosciences, Vol. 8, Neurotoxins pp. 298-310 (Conn, P. M., Ed.). San Diego: Academic Press. 
Harris, J. B. and Maltin, C. A. (1982) Myotoxic activity of the crude venom and the principal neurotoxin, 
taipoxin, of the Australian taipan, Oxyuranus cutellatus. Br. J. Pharmac. 76, 61-75. 
Harris, J. B., Johnson, M. A. and Karlsson, E. (1975) Pathological responses of rat skeletal muscle to a single 
subcutaneous injection of a toxin isolated from the venom of the Australian tiger snake, Notechis scutatus 
scutatus. Clin. exp. Pharmac. Physiol. 2, 383-404. 
Heluany, N. F., Homsi-Brandeburgo, M. I., Giglio, J. R., Prado-Franceschi, J. and Rodrigues-Simioni, L. (1992) 
Effects induced by bothropstoxin, a component from Bothrops jararacussu snake venom, on mouse and chick 
muscle preparations. Toxicon 30, 1203-1210. 
Hodgson, D., Gasparini, S., Drevet, P., Ducancel, F., Bouet, F., Boulain, J. C., Harris, J. B. and Mrnez, A. (1993) 
Production of recombinant notechis 1 I'2L, an enzymatically active mutant of a phospholipase A 2 from 
Notechis cutatus cutatus venom, as directly generated by cleavage of a fusion protein produced in Escherichia 
coll. Fur. J. Biochem. 212, 441-446. 
Holland, D. R., Clancy, L. L., Muchmore, S. W., Ryde, T. J., Einspahr, H. M., Finzel, B. C., Heinrikson, R. 
L. and Watenpaugh, K. D. (1990) The crystal structure of a lysine 49 phospholipase A 2 from the venom of 
the cottonmouth snake at 2.0-/~ resolution. J biol. Chem. 2,65, 17,649-17,656. 
Homsi-Brandeburgo, M. I., Queiroz, L. S., Santi-Neto H., Rodrigues-Simioni, L. and Giglio, J. R. (1988) 
Fractionation of Bothrops jararacussu snake venom: partial chemical characterization a d biological activity 
of bothropstoxin. Toxicon 26, 615-627. 
Kaiser, I. I., Gutirrrez, J. M., Plummer, D., Aird, S. D. and Odell, G. V. (1990) The amino acid sequence of 
a myotoxic phospholipase from the venom of Bothrops asper. Arch. Biochem. Biophys. 278, 319-325. 
Kerrigan, K. R. (1991) Venomous nakebite in Eastern Ecuador. Am. J. trop. Med. Hyg. 44, 93-99. 
Kini, R. M. and Evans, H. J. (1989) A common cytolytic region in myotoxins, hemolysins, cardiotoxins and 
antibacterial peptides. Int. J. Peptide Prot. Res. 34, 277-286. 
1422 J .M.  GUTIi~RREZ and B. LOMONTE 
Kini, R. M. and Iwanaga, S. (1986) Structure-function relationships of phospholipases. II: Charge density 
distribution and the myotoxicity of presynaptically neurotoxic phospholipases. Toxicon 24, 895-905. 
Krizaj, I., Bieber, A. L., Ritonja, A. and Gubengek, F. (1991) The primary structure of ammodytin L, a myotoxic 
phospholipase A 2 homologue from Vipera ammodytes venom. Eur. J. Biochem. 202, 1165-1168. 
Lambeau G., Schmid-Alliana, A., Lazdunski, M. and Barhanin, J. (1990) Identification and purification of a 
very high affinity binding protein for toxic phospholipases A 2in skeletal muscle. J. biol. Chem. 265, 9526-9532. 
Lambeau, G., Ancian, P., Barhanin, J. and Lazdunski, M. (1994) Cloning and expression of a membrane r ceptor 
for secretory phospholipases A 2. J. bioL Chem. 269, 1575-1578. 
Liu, C. S., Chen, J. M., Chang, C. H., Chen, S. W., Teng, C. M. and Tsai, I. H. (1991) The amino acid sequence 
and properties of an edema-inducing Lys-49 phospholipase A 2 homolog from the venom of Trimeresurus 
mucrosquamatus. Biochim. biophys. Acta 1077, 362-370. 
Liu, S Y., Yoshizumi, K., Oda, N., Ohno, M., Tokunaga, F., Iwanaga, S. and Kihara, H. (1990) Purification 
and amino acid sequence of basic protein II, a Lysine-49 phospholipase A2with low activity, from Trimeresurus 
flavoviridis venom. J. Biochem. 107, 400--408. 
Lloret, S. and Moreno, J. J. (1993) Oedema formation and degranulation of mast cells by phospholipase A: 
purified from porcine pancreas and snake venoms. Toxicon 31, 949-956. 
Lomonte B. and Carmona, E. (1992) Individual expression patterns of myotoxin isoforms in the venom of the 
snake Bothrops asper. Cornp. Biochem. Physiol. 102B, 325-329. 
Lomonte B. and Guti6rrez, J. M. (1989) A new muscle damaging toxin, myotoxin II, from the venom of the 
snake Bothrops asper (terciopelo). Toxicon 27, 725-733. 
Lomonte B. and Kahan, L. (1988) Production and partial characterization fmonoclonal ntibodies to Bothrops 
asper (terciopelo) myotoxin. Toxicon 26, 675~89. 
Lomonte B., Cerdas, L., Gen6, J. A and Guti6rrez, J. M. (1982) Neutralization of local effects of the terciopelo 
(Bothrops asper) venom by blood serum of the colubrid snake Clelia clelia. Toxicon 20, 571-579. 
Lomonte B., Guti6rrez, J. M. and Mata, E. (1985) Isolation from a polyvalent antivenom of antibodies to a 
myotoxin in Bothrops asper snake venom. Toxicon 23, 807-813. 
Lomonte B., Guti6rrez, J. M., Moreno, E. and Cerdas, L. (1987a) Antibody neutralization ofa myotoxin from 
the venom of Bothrops asper (terciopelo). Toxicon 25, 443-449. 
Lomonte B., Moreno, E. and Guti6rrez, J. M. (1987b) Detection of proteins antigenically-related o Bothrops 
asper myotoxin in crotaline snake venoms. Toxicon 25, 947-955. 
Lomonte B., Furtado M, F., Rovira, M. E,, Carmona, E., Rojas, G., Aymerich, R. and Guti6rrez, J. M. (1990a) 
South American snake venom proteins antigenically-related o Bothrops asper myotoxins. Braz. J. reed. Biol. 
Res. 23, 427-435. 
Lomonte, B., Guti(~rrez, J. M., Furtado, M. F., Otero, R., Rosso, J. P., Vargas, O., Carmona, E. and Rovira, 
M. E. (1990b) Isolation of basic myotoxins from Bothrops moojeni and Bothrops atrox snake venoms. Toxicon 
28, 1137-1146. 
Lomonte, B., Guti(~rrez, J. M., Carmona, E. and Rovira, M. E. (1990c) Equine antibodies to Bothrops asper 
myotoxin II: isolation from polyvalent antivenom and neutralizing ability. Toxicon 28, 379-384. 
Lomonte, B., Guti~rrez, J. M., Rojas, G. and Calder6n, L. (1991) Quantitation by enzyme-immunoassay of 
antibodies against Bothrops myotoxins in four commercially-available antivenoms. Toxicon 29, 695-702. 
Lomonte, B., Guti(~rrez, J. M., Ramirez, M. and Diaz, C. (1992) Neutralization of myotoxic phospholipases A2
from the venom of the snake Bothrops asper by monoclonal antibodies. Toxicon 30, 239-245. 
Lomonte, B., Tarkowski, A. and Hanson, L. A. (1993) Host response to Bothrops asper snake venom: analysis 
of edema formation, inflammatory cells, and cytokine release in a mouse model. Inflammation 17, 93-105. 
Lomonte, B., Lundgren, J., Johansson, B. and Bagge, U. (1994a) The dynamics of local tissue damage induced 
by Bothrops asper snake venom and myotoxin II on the mouse cremaster muscle: an intravital and electron 
microscopic study. Toxicon 32, 41-55. 
Lomonte, B., Guti~rrez, J. M., Borkow, G., Ovadia, M., Tarkowski, A. and Hanson, L. A. (1994b) Activity of 
hemorrhagic metalloproteinase BAH-1 and myotoxin II from Bothrops asper snake venom on capillary 
endothelial cells in vitro. Toxicon 32, 505-510. 
Lomonte, B., Tarkowski, A., Bagge, U. and Hanson, L. A. (1994c) Neutralization of the cytolytic and myotoxic 
activities of phospholipases A 2 from Bothrops asper snake venom by glycosaminoglycans of the hep- 
arin/heparan sulfate family. Biochem. Pharmac. 47, 1509-1518. 
Lomonte, B., Tarkowski, A. and Hanson, L./~. (1994d) Broad cytolytic specificity of myotoxin II, a lysine-49 
phospholipase A 2 of Bothrops asper snake venom. Toxicon 32, 1359-1369. 
Lomonte, B., Moreno, E., Tarkowski, A., Hanson, L. A,. and Maccarana, M. (1994e) Neutralizing interaction 
between heparins and myotoxin II, a Lys-49 phospholipase A 2 from Bothrops asper snake venom. Identification 
of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. 3". biol. 
Chem. 269, 29,867-29,873. 
Lugtigheid, B., Nicolaes, G. A. F., Veldhuizen, E. J. A., Slotboom, A. J., Verheij, H. M. and De Haas, G. H. 
(1993) Acylation of porcine pancreatic phospholipase A2 influences penetration and substrate head-group 
binding, depending on the position of the acylated lysine in the enzyme molecule. Eur. J. Biochern. 216, 
519-525. 
Phospholipase A2 Myotoxins from Bothrops 1423 
Maltin, C. A., Harris, J. B. and Cullen, M. J. (1983) Regeneration of mammalian skeletal muscle following the 
injection of the snake-venom toxin, taipoxin. Cell Tissue Res. 232, 565-577. 
Maraganore, J. M., Merutka, G., Cho, W., Welches, W., Kezdy, F, J. and Heinrikson, R. L. (1984) A new class 
of phospholipases A 2 with lysine in place of aspartate 49. J. biol. Chem. 159, 13,839-13,843. 
Mebs, D. and Ownby, C. L. (1990) Myotoxic components of snake venoms: their biochemical nd biological 
activities. Pharmac. Ther. 48, 223-236. 
Mebs, D. and Samejima, Y. (1986) Isolation and characterization f myotoxic phospholipases A 2 from crotalid 
venoms. Toxicon 24, 161-168. 
Melo, P. A. and Suarez-Kurtz, G. (1988) Release of sarcoplasmic enzymes from skeletal muscle by Bothrops 
jararacussu venom: antagonism by heparin and by the serum of South American marsupials. Toxicon 26, 87-95. 
Melo, P. A., Suarez-Kurtz, G., Do Nascimento, M. C., Parente, J. P. and Mors, W. B. (1988) Antagonism of 
the myotoxic and hemorrhagic effects of Bothrops venoms by extracts of Eclipta prostrata L., Asteraceae, and 
their components. Ann. Acad. brasil. Citric. 60, 263. 
Melo, P. A., Homsi-Brandeburgo, M. I., Gigiio, J. R. and Suarez-Kurtz, G. (1993) Antagonism of the myotoxic 
effect of Bothrops jararacussu venom and bothropstoxin by polyanions. Toxicon 31, 285-291. 
M6nez, A., Pillet, L., Leonetti, M., Bontems, F. and Maillere, B. (1992) Snake toxins as antigens. In: Structure 
of Antigens, pp. 293-319 (Van Regenmortel, M. H. V., Ed.). Boca Raton: CRC Press. 
Mokri, B. and Engel, A. G. (1975) Duchenne dystrophy: electron microscopic findings pointing to a basic or 
early abnormality in the plasma membrane of the muscle fiber. Neurology 25, 1111-1120. 
Moreno, E. and Guti6rrez, J. M. (1988) Body distribution of Bothrops asper (terciopelo) snake venom myotoxin 
and its relationship to pathological changes. Toxicon 26, 403-409. 
Mors, W. B., Do Nascimento, M. C., Parente, J. P., Da Silva, M. H., Melo, P. and Suarez-Kurtz, G. (1989) 
Neutralization of lethal and myotoxic activities of South American rattlesnake venom by extracts and 
constituents of the plant Eclipta prostrata (Asteraceae). Toxicon 27, 1003-1009. 
Moura, A. M., Cardoso, D. F. and Tanizaki, M. M. (1990) Differences in distribution of myotoxic proteins in 
venoms from different Bothrops species. Toxicon 28, 1293-1301. 
Moura, A. M., Desmond, H., Laing, G. and Theakston, R. D. G. (1991a) Isolation and comparison ofmyotoxins 
isolated from venoms of different species of Bothrops snakes. Toxicon 29, 713-723. 
Moura, A. M., Cardoso, D. F., Tanizaki, M. M. and Mota, I. (1991b) Neutralization of myotoxic activity of 
Bothrops venoms by antisera to purified myotoxins and to crude venoms. Toxicon 29, 1471-1480. 
Moura, A. M., Paine, M. J. I., Diniz, M. R. V., Crampton, J. M. and Theakston, R. D. G. (1993) Molecular 
cloning of a novel myotoxic phospholipase A 2 from the venom of Bothrops jararacussu. Abstracts of the XI 
European Meeting of the International Society on Toxinology, p. 66, Arezzo, Italy. 
Nakashima, K., Ogawa, T., Oda, N., Hattori, M., Sakaki, Y., Kihara, H. and Ohno, M. (1993) Accelerated 
evolution of Trimeresurusflavoviridis venom gland phospholipase A 2 isozymes. Proc. natn. Acad Sci. U.S.A. 
90, 5964-5968. 
Nikai, T., Komori, Y., Yagihashi, S., Ohara, A., Ohizumi, Y. and Sugihara, H. (1993) Isolation and 
characterization f phospholipase A 2 from Agkistrodon bilineatus (common cantil) venom. Int. J. Biochem. 25, 
879-884. 
Nishioka, S. A. and Silveira, P. V. P. (1992) A clinical and epidemiologic study of 292 cases of lance-headed 
viper bite in a Brazilian teaching hospital. Am. J. trop. Med. Hyg. 47,805-810. 
Otero, R., Tobon, G. S., Gomez, L. F., Osorio, R., Valderrama, R., Hoyos, D., Urreta, J. E., Molina, S. and 
Arboleda, J. J. (1992) Accidente ofidico en Antioquia y Choc6. Aspectos clinicos y epidemiol6gicos (marzo 
de 1989-febrero de 1990). Acta M~d. Colombiana 17, 229-249. 
Ownby, C. L. and Li, Q. (1993) Molecular cloning of the gene encoding a myotoxin from the venom of the 
broad-banded copperhead (Agkistrodon comortrix laticinctus). Abstracts of the XI European Meeting of the 
International Society on Toxinology, p. 69, Arezzo, Italy. 
Ownby, C. L., Fletcher, J. E. and Colberg, T. R. (1993) Cardiotoxin I from cobra (Naja naja atra) venom causes 
necrosis of skeletal muscle in vivo. Toxicon 31, 697-709. 
Pedersen, J. Z., de Arcuri, B. F., Morero, R. and Rufini, S. (1994) Phospholipase-like myotoxins induce rapid 
membrane l akage of non-hydrolyzable ether-lipid liposomes. Biochim. biophys. Acta 1190, 177-180. 
Pedersen, J. Z,, Lomonte, B., Massoud, R., Guben]ek, F., Guti6rrez, J. M. and Rufini, S. (1995) Autocatalytic 
acylation of phospholipase-like myotoxins. Biochemistry 34, 4670~675. 
Pestronk, A., Parhad, I. M., Drachman, D. B. and Price, D. L. 0982) Membrane myopathy: morphological 
similarities to Duchenne muscular dystrophy. Muscle Nerve 5, 209 214. 
Pruzanski, W. and Vadas, P. (1991) Phospholipase A2: a mediator between proximal and distal effectors of 
inflammation. Immun. Today 12, 143-146. 
Queiroz, L. S., Santo Neto, H., Rodrigues-Simioni, L, and Prado-Franceschi, J. (1984) Muscle necrosis and 
regeneration after envenomation by Bothrops jararacussu snake venom. Toxicon 22, 339-346. 
Renetseder, R., Brunie, S., Dijkstra, B. W., Drenth, J. and Sigler, P. B. (1985) A comparison of the crystal 
structures of phospholipase A 2 from bovine pancreas and Crotalus atrox venom. J. biol. Chem. 260, 
11,627-11,634. 
Renetseder, R., Dijkstra, B. W., Huizinga, K., Kalk, K. H. and Drenth, J. (1988) Crystal structure of bovine 
pancreatic phospholipase A 2 covalently inhibited by p-bromophenacyl-bromide. J. molec. Biol. 200, 181-188. 
1424 J.M. GUTII~RREZ and B. LOMONTE 
Roden, L., Ananth, S., Campbell, P., Curenton, T., Ekborg, G., Manzella, S., Pillion, D. and Meezan, E. (1992) 
Hepadn--an introduction. In: Heparin and Related Polysaccharides, pp. 1-20 (Lane, D. A., Bj6rk, I. and 
Lindahl, U., Eds). New York: Plenum Press. 
Rosenberg, P. (1990) Phospholipases. In:Handbook of Toxicology, pp. 67-277 (Shier, W. T. and Mebs, D., Eds.). 
New York: Marcel Dekker. 
Rosenfeld, G. (1971) Symptomatology, pathology and treatment ofsnake bites in South America. In: Venomous 
Animals and Their Venoms, Vol. 2, pp. 345-403 (Bucberl, W. and Buckley, E. E., Eds). New York: Academic 
Press. 
Rovira, M. E., Carmona, E. and Lomonte, B. (1992) Immunoenzymatic quantitation of antibodies to Bothrops 
asper myotoxins after polyvalent antivenom administration in mice. Braz. J. Med. Biol. Res. 25, 23-33. 
Rulini, S., Cesaroni, P., Desideri, A., Farias, R., Gubensek, F., Guti6rrez, J. M., Luly, P., Massoud, R., Morero, 
R. and Pedersen, J. Z. (1992) Calcium ion independent membrane l akage induced by phospholipase-like 
myotoxins. Biochemistry 31, 12,424-12,430. 
Scott, D. L., White, S. P., Otwinowski, Z., Yuan, W., Gelb, M. H. and Sigler, P. B. (1990) Interfacial catalysis: 
the mechanism of phospholipase A2. Science 250, 1541-1546. 
Scott, D. L., Achari, A., Vidal, J. C. and Sigier, P. B. (1992) Crystallographic and biochemical studies of the 
(inactive) Lys-49 phospholipase A 2 from the venom of Agkistrodon piscivorus piscivorus. J. biol. Chem. 267, 
22,645-22,657. 
Selistre, H. S., Queiroz, L. S., Cunha, O. A. B., De Souza, G. E. P. and Gigiio, J. R. (1990) Isolation and 
characterization f hemorrhagic, myonecrotic and edema-inducing toxins from Bothrops insularis (jararaca 
ilhoa) snake venom. Toxicon 28, 261-273. 
Sharp, N. J. H., Kornegay, J. N., Bartlett, R. J., Hung, W. Y. and Dykstra, M. J. (1993) Notexin-induced muscle 
injury in the dog. J. neurol. Sci. 116, 73-81. 
Takasaki, C., Yutani, F. and Kajiyashiki, T. (1990) Amino acid sequences of eight phospholipases A 2from the 
venom of Australian king brown snake, Pseudechis australis. Toxicon 28, 329-339. 
Tomasselli, A. G., Hui, J., Fisher, J., Zurcher-Neely, H., Reardon, I. M., Oriaku, E., Kezdy, F. J. and Heinrikson, 
R. L. (1989) Dimerization and activation of porcine pancreatic phospholipase A 2 via substrate l vel acylation 
of lysine 56. J. biol. Chem. 264, 10,041-10,047. 
Valiente, C., Moreno, E., Sittenfeld, A., Lomonte, B. and (3uti6rrez, J. M. (1992) An electrophoretic study on 
phospholipase A2 isoenzymes in the venoms of Central American crotaline snakes. Toxicon 30, 815-823. 
Van Den Bergh, C. J., Slotboom, A. J., Verheij, H. M. and De Haas, G. H. (1989) The role of Asp-49 and other 
conserved amino acids in phospholipases A2and their importance for enzymatic activity. J. cell. Biochem. 39, 
379-390. 
Vishwanath, B. S., Fawzy, A. A. and Franson, R. C. (1988) Edema-inducing activity of phospholipase A 2purified 
from human synovial fluid and inhibition by aristolochic acid. Inflammation 12, 549-561. 
Vracko, R. and Benditt, E. P. (1972) Basal lamina: the scaffold for orderly cell replacement. Observations on 
regeneration f injured skeletal muscle fibers and capillaries. J. Cell Biol. 55, 406-419. 
Wery, J. P., Schevitz, R. W., Clawson, D. K., Bobbitt, J. L., Dow, E. R., Gamboa, G., Goodson, T., Hermann, 
R. B., Kramer, R. M., McClure, D. B., Mihelich, E. D., Putnam, J. E., Sharp, J. D., Stark, J. D., Teater, 
C., Warrick, M. W. and Jonesz N. D. (1991) Structure of recombinant human rheumatoid arthritic synovial 
fluid phospholipasc A 2 at 2.2 A resolution. Nature 352, 79-82. 
Westerlund, B., Nordlund, P., Uhlin, U., Eaker, D. and Eklund, H. (1992) The three-dimensional structure of 
notexin, a presynaptic neurotoxic phospholipase A 2 at 2.0 A resolution. FEBS Lett. 3@1, 159-164. 
Yoshizumi, K., Liu, S. Y., Miyata, T., Salta, S., Ohno, M., lwanaga, S. and Kihara, H. (1990) Purification and 
amino acid sequence of basic protein I, a lysine-49 phospholipase A 2 with low activity, from the venom of 
Trimeresurus flavoviridis (habu snake). Toxicon 28, 43-54. 
